Abstract
The invention relates to biologically active dibenzodiazepinone analogs represented by Formula I, to methods of producing them, to pharmaceutical compositions comprising them and to methods of treating neoplastic conditions.
Claims
- A compound selected from the group consisting of Compounds 131 to 161, or a pharmaceutically acceptable salt thereof:
- The compound of claim 1, wherein said compound is selected from the group consisting of Compounds 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142 and 143, or a pharmaceutically acceptable salt thereof.
- The compound of claim 1, wherein said compound is selected from the group consisting of Compounds 144, 145, 146, 147, 148, 149, 150, 151, 152, 153 and 154, or a pharmaceutically acceptable salt thereof.
- The compound of claim 1, wherein said compound is selected from the group consisting of Compounds 155, 156, 157 and 158, or a pharmaceutically acceptable salt thereof.
- The compound of claim 1, wherein said compound is selected from the group consisting of Compounds 159, 160 and 161, or a pharmaceutically acceptable salt thereof.
- A process for producing a compound of claim 1, said process comprising chemically modifying Compound 1: wherein said chemical modification comprises at least one step selected from the group consisting of: N-alkylations, N-acylations, O-alkylations, O-acylations, aromatic halogenation, farnesyl hydrogenation, farnesyl epoxidation, farnesyl dihydroxylation, farnesyl hydration, farnesyl hydroalkoxylation, farnesyl hydroamidation, and farnesyl ozonolysis.
- The process of claim 6, wherein said chemical modification comprises at least one step selected from the group consisting of: N-alkylations, O-acylations, farnesyl hydrogenation, and farnesyl hydroalkoxylation.
- A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
- A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.
- A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier.
- A pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier.
- A pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically acceptable carrier.
Owners (US)
-
Thallion Pharmaceuticals Inc
(Jul 20 2009)
Explore more patents:
Applicants
-
Thallion Pharmaceuticals Inc
Explore more patents:
Inventors
-
Mcalpine James B
Explore more patents:
-
Banskota Arjun H
Explore more patents:
-
Aouidate Mustapha
Explore more patents:
CPC Classifications
-
C07D243/38
Explore more patents:
-
C07D401/14
Explore more patents:
-
C07D405/04
Explore more patents:
-
C07D405/06
Explore more patents:
-
C07D405/14
Explore more patents:
IPC Classifications
-
C07D243/10
Explore more patents:
-
A61K31/55
Explore more patents:
Download PDF
Document Preview
Document History
- Publication: Feb 2, 2010
-
Application:
Dec 21, 2007
US 96285507 A
-
Priority:
Dec 21, 2007
US 96285507 A
-
Priority:
Oct 20, 2005
US 25365805 A
-
Priority:
Sep 27, 2005
US 23539805 A
-
Priority:
Jul 22, 2005
US 70147205 P
-
Priority:
Feb 11, 2005
CA 2497031 A
-
Priority:
Jan 28, 2005
US 64738105 P
-
Priority:
Nov 8, 2004
US 62565304 P
-
Priority:
Sep 27, 2004
US 95143604 A
-
Priority:
Jan 21, 2004
US 76210704 A
-
Priority:
Nov 10, 2003
US 51828603 P
-
Priority:
Aug 7, 2003
US 49299703 P
-
Priority:
Jan 21, 2003
US 44112603 P